The Eurofins network of companies achieved solid growth in most business lines in Q1 2025:
“Despite geopolitical and macroeconomic uncertainties increasing at the global level and in specific regions, Eurofins has been able to deliver resilient results in the first quarter of 2025, particularly in sizable business lines including Food and Feed Testing, Environment Testing, and BioPharma Product Testing, where Eurofins is a global leader. Our performance demonstrates not only the non-cyclical demand for our services under challenging economic conditions, but also the durability of our business model and the focus of our organisation.
Meanwhile, we have been making further progress to improve our operational and financial performance as well as in executing our value creation strategy. Thanks to the dedication of Eurofins teams to pricing attainment, better capacity utilisation and strict management of capex and working capital, we remain on track to increase our profitability and cash generation in 2025 above the levels achieved in 2024. In terms of strategy and capital allocation, we have continued to expand and strengthen our network footprint by completing 11 acquisitions and initiating 5 start-ups and 14 blood collection points, while also opportunistically allocating substantial capital to repurchase our shares at attractive valuation levels.
Although we are cautious in the current uncertain economic climate, we remain confident in our long-term value creation strategy of further investing in our unique laboratory network, leveraging digitalisation and automation and improving client service quality, while also pragmatically sustaining our strong balance sheet and continuing to prudently allocate capital.”
Eurofins will hold a conference call with analysts and investors today at 15:00 CEST to discuss the results and the performance of Eurofins, as well as its outlook, and will be followed by a questions and answers (Q&A) session.
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
Eurofins is Testing for Life. The Eurofins Scientific S.E. network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.
Shares in Eurofins Scientific S.E. are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins Scientific S.E. through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific S.E.’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific S.E. disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.